- Home
- ARGX
ARGX
argenx SE
as 07-26-2024 4:00pm EST
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
| Founded: | 2008 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 26.5B | IPO Year: | 2017 |
| Target Price: | $531.83 | AVG Volume (30 days): | 378.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $327.73 - $532.60 | Next Earning Date: | 07-25-2024 |
| Revenue: | $38,597,849 | Revenue Growth: | 21.73% |
| Revenue Growth (this year): | 5238.7% | Revenue Growth (next year): | 37.22% |
Latest argenx SE News
ARGX Breaking Stock News: Dive into ARGX Ticker-Specific Updates for Smart Investing
Morningstar Research
a day ago
Analyst Report: argenx SE
MT Newswires
2 days ago
Argenx Swings to Q2 Profit, Total Operating Income Rises
GlobeNewswire
2 days ago
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire
9 days ago
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
Insider Monkey
11 days ago
What Made argenx SE (ARGX) Rise in Q2?
MT Newswires
11 days ago
Argenx, Zai Lab Get Chinese Regulator's Nod for Subcutaneous Add-on Injection Targeting Eneralized Myasthenia Gravis
GlobeNewswire
11 days ago
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Business Wire
11 days ago
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Compare ARGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARGX argenx SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.